composed of the a- and ß-chains of the MHC class I1
I-E molecule fused to antibody V regions derived
from anti-human CD4 mAb MT310. Expression vectors
were constructed containing the functional,
rearranged gene segments coding for the V region
domains of the antibody H and L chains in place of
the first domains of the complete structural genes
of the I-E a- and ß-chains, respectively. Celltsr ansfected
with both hybrid genes expressed a stable
protein product on the cell surface. The chimeric
molecule exhibited the idiotype of the antibody
MT310 as shown by binding to the anti-idiotypic
mAb 20-46. A protein of the anticipated molecular
mass was immunoprecipitated witha nti-mouse IgG
antiserum. Furthermore, human soluble CD4 did
bind to thetr ansfected cell line, demonstrating that
the chimeric protein possessed the binding capacity
of the original mAb. Thus, the hybrid molecule retained:
1) the properties of a MHC class I1 protein
with regardt o correct chain assembly and transport
to the cell surface: as well as 2) the Ag binding
capacity of the antibody genes used. Thgee neration
of hybrid MHC class I1 molecules with highly specific,
non-MHC-restricted bindingc apacities will be
useful for studying MHC class 11-mediated effector
functions such as selection of the T cell repertoire
in thymus of transgenic mice
